Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260684 · ClinicalTrials.gov registry record
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 716
- Enrollment target
NCT05260684 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 716 participants.
The verdict
NCT05260684 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 716 participants
- Enrollment target
Study Summary
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Interventions
- DRUG Vemurafenib
- DRUG Binimetinib
- DRUG Cobimetinib
- DRUG Dabrafenib
- DRUG Encorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260684
The ClinicalTrials.gov registry entry for NCT05260684 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vemurafenib is the first listed.
NCT05260684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05260684 about?
NCT05260684 is a clinical study titled "Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US". This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
What is the current status of trial NCT05260684?
This trial is currently completed. The enrollment target is 716 participants. The study started on 2022-01-17. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05260684?
The interventions under investigation include: Vemurafenib (DRUG), Binimetinib (DRUG), Cobimetinib (DRUG), Dabrafenib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT05260684?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.